Biotech News

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

Vaxcyte (PCVX)VaxcyteEarnings

SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026.

Related news

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

Stock data

Close
58.89 USD
Market cap
6.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States